Arcellx-RGB-logo-large.png
Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting
June 04, 2021 09:00 ET | Arcellx, Inc.
GAITHERSBURG, Md., June 04, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, announced the presentation of positive clinical data from the first 12...
Arcellx-RGB-logo-large.png
Arcellx to Present Data from Phase 1 Study of CART-ddBCMA Demonstrating Continued Positive Response in Patients with Relapsed and Refractory Multiple Myeloma at the 2021 ASCO Annual Meeting
May 19, 2021 17:00 ET | Arcellx, Inc.
GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, today announced the release of updated clinical data from the first 12 evaluable...
Arcellx-RGB-logo-large.png
Preclinical Data of Arcellx’s Novel Synthetic CAR-T Binding Domain Presented at the 2021 ASGCT Annual Meeting and the 2021 PEGS Summit
May 13, 2021 10:00 ET | Arcellx, Inc.
Novel synthetic binding domain used in CART-ddBCMA demonstrates potent anti-tumor activity Results underpin Arcellx’s ongoing first-in-human Phase 1 CART-ddBCMA trial in patients with relapsed and...
Arcellx-RGB-logo-large.png
Arcellx Announces Executive Appointments
April 19, 2021 07:30 ET | Arcellx, Inc.
GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s...
Arcellx-RGB-logo-large.png
Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
April 13, 2021 07:00 ET | Arcellx, Inc.
GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to...
Arcellx-RGB-logo-large.png
Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
April 06, 2021 16:00 ET | Arcellx, Inc.
GAITHERSBURG, Md., April 06, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared...
Arcellx-RGB-logo-large.png
Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer
January 26, 2021 16:00 ET | Arcellx, Inc.
GAITHERSBURG, Md., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced the...
Arcellx-RGB-logo-large.png
Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma
December 07, 2020 10:00 ET | Arcellx, Inc.
- Company announces initial results in first-in-human trial utilizing novel synthetic binding domain - - 6/6 (100%) overall response rate (ORR) per International Myeloma Working Group (IMWG)...
Arcellx-RGB-logo-large.png
Arcellx Announces Clinical Data to be Presented at the 62nd American Society of Hematology (ASH) Annual Meeting
November 05, 2020 09:30 ET | Arcellx, Inc.
Presentation to include clinical data from Arcellx’s ongoing Phase 1 study of CART-ddBCMA, a genetically engineered cell therapy utilizing the company’s novel synthetic binding domain for the...
Arcellx-RGB-logo-large.png
Arcellx to Present at Jefferies Virtual Cell Therapy Summit
October 02, 2020 07:08 ET | Arcellx, Inc.
GAITHERSBURG, Md., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Arcellx today announced that David Hilbert, Chief Executive Officer, will present at the following upcoming investor conference. Presentation...